Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Childhood Ependymoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Ependymoma in children and adolescents

Source population
pediatric
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      unresolved
      derivation note
      Derived from NCI topic(s): Childhood Ependymoma. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      1 more-specific settings
      recurrent Childhood Ependymoma →

      Study evidence for this setting

      5 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01462695 · Source cited / selected · Scope: narrower

      Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

      1 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03210714 · Registry condition search · Scope: narrower

      Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03233204 · Registry condition search · Scope: narrower

      Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03387020 · Registry condition search · Scope: narrower

      Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT03526250 · Source cited / selected · Scope: narrower

      Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell C

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-ependymoma-pediatric
        binding id
        ncit-C3017
        source collection
        ncit-concept
        source key
        C3017
        source excerpt
        Source null
        match status
        ambiguous
        match note
        Resolution status: ambiguous.
        recorded at
        2026-09-10T00:00:00Z
      2. release id
        clinical-indications-draft-1
        disease state id
        ds-ependymoma-pediatric
        binding id
        ncit-C8578
        source collection
        ncit-concept
        source key
        C8578
        source excerpt
        Source null
        match status
        ambiguous
        match note
        Resolution status: ambiguous.
        recorded at
        2026-09-10T00:00:00Z
      3. release id
        clinical-indications-draft-1
        disease state id
        ds-ependymoma-pediatric
        binding id
        ncit-C9092
        source collection
        ncit-concept
        source key
        C9092
        source excerpt
        Source null
        match status
        ambiguous
        match note
        Resolution status: ambiguous.
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice